Amsterdam E A, Lee G, Morrison S, Tonkin M J, DeMaria A N, Mason D T
Am J Cardiol. 1976 Aug;38(2):195-9. doi: 10.1016/0002-9149(76)90149-1.
The efficacy of tolamolol, a cardioselective beta adrenergic blocking agent, was evaluated in the treatment of cardiac arrhythmias in 27 patients. Nineteen patients had supraventricular arrhythmias and eight had ventricular arrhythmias. Evaluation was by doulbe-blind randomized trial in 23 patients. Tolamolol was effective in reducing ventricular rate in 17 (85 percent) of 19 patients with supraventricular arrhythmias and resulted in conversion to sinus rhythm in 2 of the 17. The mean ventricular rate in 17 patients decreased from 135 to 102/min 10 minutes after initiation of administration of tolamolol and gradually decreased further to 93/min after 60 minutes. Reduction in ventricular rate was sustained for 2 hours of monitoring undergone by all patients and for 4 and 6 hours monitoring in two subgroups. Among the eight patients with ventricular ectopic beats, tolamolol reduced their frequency in four patients and had no effect in four. Six patients had chronic obstructive pulmonary disease and experienced no adverse clinical effects on respiratory function in association with administration to tolamolol. Untoward effects occurred in 10 patients, including hypotension in 3, 1 of whom required vasopressor therapy. Other side effects were sedation, nausea, dyspnea and warmth in the chest, all of which were mild and transient, requiring no treatment. Cardioselective beta adrenergic blockade with tolamolol was highly effective in controlling ventricular rate in supraventricular arrhythmias and reduced the frequency of ventricular ectopic beats in half of the small group of patients with this arrhythmia. It is particularly applicable in patients with obstructive pulmonary disease in whom cardiac beta adrenergic blockade is indicated. Hypotension is an important potential side effect.
对一种心脏选择性β肾上腺素能阻滞剂托拉洛尔治疗心律失常的疗效进行了评估，共纳入27例患者。19例为室上性心律失常患者，8例为室性心律失常患者。对23例患者采用双盲随机试验进行评估。托拉洛尔能有效降低19例室上性心律失常患者中17例（85%）的心室率，其中17例中有2例转为窦性心律。17例患者在开始使用托拉洛尔后10分钟内心室率从135次/分钟降至102次/分钟，60分钟后进一步逐渐降至93次/分钟。所有患者均监测2小时，两个亚组分别监测4小时和6小时，心室率降低情况持续存在。在8例室性早搏患者中，托拉洛尔使4例患者的早搏频率降低，4例无效。6例患有慢性阻塞性肺疾病的患者在使用托拉洛尔后呼吸功能未出现不良临床影响。10例患者出现不良反应，包括3例低血压，其中1例需要血管升压药治疗。其他副作用包括镇静、恶心、呼吸困难和胸部发热，均较轻微且为一过性，无需治疗。托拉洛尔进行心脏选择性β肾上腺素能阻滞在控制室上性心律失常的心室率方面非常有效，并且在一小部分此类心律失常患者中使室性早搏频率降低了一半。它特别适用于需要进行心脏β肾上腺素能阻滞的阻塞性肺疾病患者。低血压是一个重要的潜在副作用。
